Other Services

This Service

A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

This Project

INDRA is developed by indralabs, a part of the Harvard Medical School Laboratory of Systems Pharmacology.

This project, indra_db, is also developed by the indralab team. For more information on how we procure our sources, you can go here. This work was funded by ARO grant W911NF‐15‐1‐0544 under the DARPA Communicating with Computers program.

IndraLab

Statements

ZUP1 activates patients developing resistance. 1 / 1

| 1

➶

eidos

"9 A significant challenge with proteasome-targeted therapeutics is drug resistance leading to relapse and death in the treated patients.6 Recent research has discovered that increased activity of DUBs resulted in MM patients developing a resistance to Bortezomib , while combinational treatment of DUB inhibitors and proteasome inhibitors led to enhanced Bortezomib efficacy.1 , 3 , 10 , 11 This finding coupled with the cost of molecularly-targeted therapeutics , and the potential for severe side effects like peripheral neuropathy , has created an urgent need for more advanced biochemical screening methods for members of the UPS including the proteasome and DUBs ."

32831622

Our Sources:

INDRA allows us to combine the results from a multitude of sources. In particular, the INDRA Database draws on the following...